Wenming Gao

Wenming Gao is a skilled research scientist with extensive experience in the pharmaceutical and biotechnology sectors, specializing in immune-oncology and drug development. Currently serving as a Research Scientist I at Bristol-Myers Squibb since September 2018, Wenming develops high throughput cell-based assays for cancer targets PRMT5 and MAT2A. Prior roles include Senior Research Associate positions at Portola Pharmaceuticals and Cytomx Pharmaceuticals, where significant contributions were made in characterizing antidotes for Factor Xa inhibitors and validating novel protease substrates, respectively. Previous experiences also encompass research at Genentech, Sutrobio Pharmaceuticals, Celgene, and Agensys, focusing on assay development, mechanism of action studies, and target validation in various cancer research contexts. Wenming holds a degree from the University of Gothenburg, obtained between 2001 and 2004.